Mikhail A. Golubev
Mikhail A. Golubev has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya S. Babkina
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
1 shared publication - Arkady M. Golubev
V. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
1 shared publication - Maksim A. Lyubomudrov
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Ministry of Education and Science of Russia
1 shared publication - Mikhail Pisarev
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow 107031, Russia
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 6 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 5040
Neuron-Specific Enolase—What Are We Measuring?
Since the discovery of the neuron-specific protein by Moore and McGregor in 1965, tens of thousands of studies have investigated the basic and applied significance of neuron-specific enolase (NSE). This promising biomarker, according to many researchers, has not found widespread use in clinical practice, particularly in acute cerebrovascular accidents. Moreover, the several studies refuting the usefulness of serum NSE measurement in critically ill patients leads us to consider the reasons for such contradictory conclusions. In this article, we have analyzed the main directions in the study of NSE and expressed our perspective on the reasons for the contradictory results and the difficulties in implementing the results of these studies in clinical practice. In our opinion, the method of the enzyme-linked immunosorbent assay (ELISA) used in the majority of the studies is inappropriate for the evaluation of NSE as a marker of central nervous system damage, because it does not allow for the differentiation of heterodimers of enolases and the assessment of the enzymatic activity of this group of enzymatic proteins. Therefore, the methodological approach for the evaluation of NSE (γγ-enolase) as a biomarker needs to be elaborated and improved. Furthermore, the specificity of the applied research methods and the appropriateness of the continued use of the term “neuron-specific enolase” must be addressed.
- 6 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 5040
Top Cited PapersOpen AccessNeuron-Specific Enolase—What Are We Measuring?
Since the discovery of the neuron-specific protein by Moore and McGregor in 1965, tens of thousands of studies have investigated the basic and applied significance of neuron-specific enolase (NSE). This promising biomarker, according to many researchers, has not found widespread use in clinical practice, particularly in acute cerebrovascular accidents. Moreover, the several studies refuting the usefulness of serum NSE measurement in critically ill patients leads us to consider the reasons for such contradictory conclusions. In this article, we have analyzed the main directions in the study of NSE and expressed our perspective on the reasons for the contradictory results and the difficulties in implementing the results of these studies in clinical practice. In our opinion, the method of the enzyme-linked immunosorbent assay (ELISA) used in the majority of the studies is inappropriate for the evaluation of NSE as a marker of central nervous system damage, because it does not allow for the differentiation of heterodimers of enolases and the assessment of the enzymatic activity of this group of enzymatic proteins. Therefore, the methodological approach for the evaluation of NSE (γγ-enolase) as a biomarker needs to be elaborated and improved. Furthermore, the specificity of the applied research methods and the appropriateness of the continued use of the term “neuron-specific enolase” must be addressed.